Open access · CC-BY
via OpenAlex
Fisetin reduces the senescent tubular epithelial cell burden and also inhibits proliferative fibroblasts in murine lupus nephritis
Shogo Ijima, Yuki Saito, Kentaro Nagaoka, Sena Yamamoto, Tsukasa Sato, Norihiro Miura, Taiki Iwamoto, Maki Miyajima, Takako Chikenji
Frontiers in Immunology · 2022 · ▲ 47 citations
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by the involvement of multiple organs. Lupus nephritis (LN) is a major risk factor for overall morbidity and mortality in SLE patients. Hence, designing effective drugs is pivotal for treating individuals with LN. Fisetin plays a senolytic role by specifically eliminating senescent cells, inhibiting cell proliferation, and exerting anti-inflammatory, anti-oxidant, and anti-tumorigenic effects. However, limited research has been conducted on the utility and therapeutic mechanisms of fisetin in chronic inflammation. Similarly, whether the effects of fisetin depend on cell type remains unclear. In this study, we found that LN-prone MRL/lpr mice demonstrated accumulation of Ki-67-positive myofibroblasts and p15INK4B-positive senescent tubular epithelial cells (TECs) that highly expressed transforming growth factor β (TGF-β). TGF-β stimulation induced senescence(definition) of NRK-52E renal TECs and proliferation of NRK-49F renal fibroblasts, suggesting that TGF-β promotes senescence and proliferation in a cell type-dependent manner, which is inhibited by fisetin treatment in vitro. Furthermore, fisetin treatment in vivo reduced the number of senescent TECs and myofibroblasts, which attenuated kidney fibrosis, reduced senescence-associated secretory phenotype (SASP) expression, and increased TEC proliferation. These data suggest that the effects of fisetin vary depending on the cell type and may have therapeutic effects in complex and diverse LN pathologies.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fimmu.2022.960601
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Ijima, S., Saito, Y., Nagaoka, K., Yamamoto, S., Sato, T., Miura, N., Iwamoto, T., Miyajima, M., & Chikenji, T. (2022). Fisetin reduces the senescent tubular epithelial cell burden and also inhibits proliferative fibroblasts in murine lupus nephritis. <em>Frontiers in Immunology</em>. https://doi.org/10.3389/fimmu.2022.960601
Vancouver
Ijima S, Saito Y, Nagaoka K, Yamamoto S, Sato T, Miura N, et al. Fisetin reduces the senescent tubular epithelial cell burden and also inhibits proliferative fibroblasts in murine lupus nephritis. Frontiers in Immunology. 2022. doi:10.3389/fimmu.2022.960601.
BibTeX
@article{shogo2022Fiseti,
title = {Fisetin reduces the senescent tubular epithelial cell burden and also inhibits proliferative fibroblasts in murine lupus nephritis},
author = {Shogo Ijima and Yuki Saito and Kentaro Nagaoka and Sena Yamamoto and Tsukasa Sato and Norihiro Miura and Taiki Iwamoto and Maki Miyajima and Takako Chikenji},
journal = {Frontiers in Immunology},
year = {2022},
doi = {10.3389/fimmu.2022.960601},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The FASEB Journal 2025
Open access · OA
Senolytic procyanidin C1 alleviates renal fibrosis by promoting apoptosis of senescent renal tubular epithelial cells
British Journal of Pharmacology 2011
Open access · OA
Honokiol ameliorates renal fibrosis by inhibiting extracellular matrix and pro‐inflammatory factors in vivo and in vitro
Cell & Bioscience 2022
Open access · CC-BY
The multifaceted role of the SASP in atherosclerosis: from mechanisms to therapeutic opportunities
JCI Insight 2023
Open access · CC-BY
Tubular cell senescence promotes maladaptive kidney repair and chronic kidney disease after cisplatin nephrotoxicity
Aging 2016
Open access · CC-BY
Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway
Journal of Cellular Physiology 2019
Citation only